Skip to main content
. 2017 Jul 10;36(43):6041–6048. doi: 10.1038/onc.2017.215

Figure 5.

Figure 5

Effect of Ezh2 inhibitor treatment in BAF-mutant, BAF-wild-type and BAF/Ras double-mutant MEF BBCE cell lines. (a) Cells mutant in Ras and BAF (AA_2-1), wild type in Ras and BAF (Spont_5), and cells with BAF mutation in a wild-type Ras background (MNNG_4-2) were seeded at low density in standard six-well plates and treated with Ezh2 inhibitor GSK126 for 7 days. Cells were then visualized using crystal violet. The result is representative of three independent experiments. (b) Cells mutant in Ras and BAF (AA_2-1), wild type in Ras and BAF (Spont_5), and cells with BAF mutation in a wild-type Ras background (MNNG_4-2) were plated in 96-well plates and treated with GSK126 for up to 96 h. Relative absorbance (related to treatment with dimethyl sulfoxide (DMSO) carrier), indicative of cell viability was measured at 24, 48, 72 and 96 h. Columns represent mean value and s.e.m.derived from three independent experiments. (c) Immunoblots for the H3K27me3 chromatin mark in all tested cell lines upon GSK126 treatment. Immunoblot was carried out using acid-extracted histones. Histone H3 immunoblot was performed to control for the baseline level of the protein. The blots were cropped for display.